NCI Selects Open Biosystems to Validate Gene Silencing Capability of shRNAmir Clones
Open Biosystems, Inc. has been selected by the National Cancer Institute (NCI) to verify the effectiveness of lentiviral microRNA-adapted short hairpin RNA technology in 135 specifically targeted cancer genes.
Increasingly, researchers and scientists, including the NCI, are utilizing shRNAmir technology to develop potential treatments in disease areas such as cancer.
The NCI has funded Open Biosystems to functionally validate the knock-down efficiency of shRNAmir lentiviral constructs when targeting specific cancer genes.
This validation study will provide researchers with a validated set of cancer gene targeting reagents and data that can be utilized to better identify and study the specific genes involved in the development of cancer.
"RNAi has great potential to dramatically impact the future of cancer diagnostics and treatment," said Troy Moore, chief technical officer of Open Biosystems.
"Open Biosystems’ shRNAmir technology is already helping leading cancer research organizations advance efforts."
"This validation study will further highlight the benefits of shRNAmir technology and encourage widespread adoption."
"Clearly the NCI sees value in shRNAmir and we are excited to participate in providing it to the cancer research community."
As a result of the study, in Q1 2007, researchers will be able to access cancer-specific shRNAmir reagents through Open Biosystems and the corresponding knock-down data through the NCI.